Varicella

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine

982%

Small Molecule

218%

+ 34 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Sharp TherapeuticsPA - Pittsburgh

9 programs

VARIVAX®Phase 41 trial

ProQuad®Phase 31 trial

VARIVAX® PE34 ProcessPhase 31 trial

VARIVAX™Phase 31 trial

VARIVAX™ New Seed ProcessPhase 31 trial

+4 more programs

Active Trials

NCT01062061Completed754Est. May 2012

NCT00432042Completed955Est. Mar 2008

NCT03239873Completed600Est. Apr 2019

+6 more trials

MSDIreland - Ballydine

9 programs

VARIVAX®Phase 4

ProQuad®Phase 3

VARIVAX® PE34 ProcessPhase 3

VARIVAX™Phase 3

VARIVAX™ New Seed ProcessPhase 3

+4 more programs

Medica CorpMA - Bedford

1 program

varicella-1Phase 41 trial

Active Trials

NCT02173899Completed716Est. Aug 2014

ViiV HealthcareNC - Durham

9 programs

Collection of clinical samplesPhase 3

GSK Biological's investigational MMRV vaccine 208136Phase 3Vaccine

Priorix-tetra™Phase 3

valaciclovir HCl granulesPhase 3

MeMuRu-OKAPhase 2

+4 more programs

GSKLONDON, United Kingdom

9 programs

ValaciclovirN/ASmall Molecule1 trial

MeMuRu-OKAPHASE_21 trial

Priorix-Tetra™PHASE_21 trial

VarilrixPHASE_21 trial

VarilrixTMPHASE_21 trial

+4 more programs

Active Trials

NCT01390857Completed379Est. May 2010

NCT00353288Completed446Est. Nov 2006

NCT00578175Completed1,851Est. Mar 2009

+6 more trials

Merck & Co.RAHWAY, NJ

5 programs

VARIVAX™N/A

ProQuad®PHASE_3

VARIVAX® PE34 ProcessPHASE_3

Varicella Virus Vaccine LivePHASE_3Vaccine

VARIVAX®PHASE_4

Colorado TherapeuticsCO - Louisville

1 program

varicella vaccineN/AVaccine1 trial

Active Trials

NCT02692066Withdrawn0Est. Apr 2016

GC BiopharmaKorea - Yongin

1 program

MG1111PHASE_21 trial

Active Trials

NCT05422508Recruiting230Est. Jun 2027

SanofiPARIS, France

1 program

Live Attenuated Varicella Virus VaccinePHASE_4Vaccine1 trial

Active Trials

NCT00830648Completed122Est. Dec 2009

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

Medica Corpvaricella-1

SanofiLive Attenuated Varicella Virus Vaccine

Sharp TherapeuticsVARIVAX®

Sharp TherapeuticsVARIVAX™

Sharp TherapeuticsVARIVAX® PE34 Process

Sharp TherapeuticsVARIVAX™ VEP

Sharp TherapeuticsVARIVAX™ New Seed Process

GSKGSK Biological's investigational MMRV vaccine 208136

Sharp TherapeuticsVaricella Virus Vaccine Live

Sharp TherapeuticsProQuad®

GSKPriorix-tetra™

Sharp TherapeuticsVaricella Virus Vaccine Live

GSKCollection of clinical samples

GSKvalaciclovir HCl granules

GC BiopharmaMG1111

Showing 15 of 22 trials with date data

Clinical Trials (22)

Total enrollment: 14,633 patients across 22 trials

NCT02173899 Medica Corpvaricella-1

Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine

Start: Jun 2014Est. completion: Aug 2014716 patients

Phase 4Completed

NCT00830648 SanofiLive Attenuated Varicella Virus Vaccine

Safety of a Second Dose of Biken's Varicella Vaccine

Start: Jan 2009Est. completion: Dec 2009122 patients

Phase 4Completed

NCT00432731 Sharp TherapeuticsVARIVAX®

Safety Study of a Refrigerator-stable Formulation of VARIVAX®

Start: Dec 2004Est. completion: Sep 2005500 patients

Phase 4Completed

NCT03843632 Sharp TherapeuticsVARIVAX™

Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)

Start: Mar 2019Est. completion: Jun 2020150 patients

Phase 3Completed

NCT03239873 Sharp TherapeuticsVARIVAX® PE34 Process

Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)

Start: Oct 2017Est. completion: Apr 2019600 patients

Phase 3Completed

NCT01626794 Sharp TherapeuticsVARIVAX™ VEP

A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062)

Start: Jul 2014Est. completion: Oct 20150

Phase 3Withdrawn

NCT02062502 Sharp TherapeuticsVARIVAX™ New Seed Process

Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)

Start: Mar 2014Est. completion: Oct 2015611 patients

Phase 3Completed

NCT00969436 GSKGSK Biological's investigational MMRV vaccine 208136

Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM

Start: Nov 2009Est. completion: Feb 2011450 patients

Phase 3Completed

NCT00822237 Sharp TherapeuticsVaricella Virus Vaccine Live

Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)

Start: Jan 2009Est. completion: Dec 2009598 patients

Phase 3Completed

NCT00432042 Sharp TherapeuticsProQuad®

Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)

Start: Jan 2007Est. completion: Mar 2008955 patients

Phase 3Completed

NCT00226499 GSKPriorix-tetra™

Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox

Start: Sep 2005Est. completion: Oct 20065,803 patients

Phase 3Completed

NCT00496327 Sharp TherapeuticsVaricella Virus Vaccine Live

Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056)

Start: Jun 2005Est. completion: Oct 2005100 patients

Phase 3Completed

NCT00127608 GSKCollection of clinical samples

Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients

Start: Jun 2005Est. completion: Jul 200636 patients

Phase 3Completed

NCT00169416 GSKvalaciclovir HCl granules

Evaluation Of Valaciclovir In Patients With Chickenpox

Start: Mar 2005Est. completion: Aug 200543 patients

Phase 3Completed

NCT05422508 GC BiopharmaMG1111

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Start: Jul 2022Est. completion: Jun 2027230 patients

Phase 2Recruiting

NCT00578175 GSKPriorix-Tetra™

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

Start: Nov 2007Est. completion: Mar 20091,851 patients

Phase 2Completed

NCT00568334 GSKVarilrix

Study of Two Formulations of GSK Biologicals' Varicella Vaccine

Start: Nov 2007Est. completion: Apr 2008244 patients

Phase 2Completed

NCT00353288 GSKMeMuRu-OKA

Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™

Start: Mar 2006Est. completion: Nov 2006446 patients

Phase 2Completed

NCT00792623 GSKVarilrixTM

Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).

Start: Sep 2003Est. completion: Sep 200745 patients

Phase 2Completed

NCT02692066 Colorado Therapeuticsvaricella vaccine

Response and Clearance of Viral DNA Following Administration of Live Attenuated Varicella Vaccine.

Start: Apr 2016Est. completion: Apr 20160

N/AWithdrawn

NCT01390857 GSKValaciclovir

Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)

Start: Nov 2007Est. completion: May 2010379 patients

N/ACompleted

NCT01062061 Sharp TherapeuticsVARIVAX™

Re-examination Study For Varivax (V210-059 AM2)

Start: Jun 2007Est. completion: May 2012754 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

18 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 14,633 patients

9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.